Compare AstraZeneca plc (AZN) vs Baker Hughes Co (BKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Baker Hughes Co — how do they compare? AstraZeneca plc trades at $158.47 (market cap $248.14B), while Baker Hughes Co trades at $64.64 (market cap $64.34B). The key difference: AstraZeneca plc is far larger — about 3.9× Baker Hughes Co's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | BKR | |
|---|---|---|
Market Cap | $248.14B | $64.34B |
Sector | Health | Energy |
52-Week High | $209.48 | $69.67 |
52-Week Low | $147.06 | $42.51 |
Enterprise Value | $275.41B | $64.86B |
Dividend Yield | 2.01% | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Baker Hughes (BKR) trades at $64.69, up 0.97% today, with strong technical and fundamental momentum. The stock shows bullish moving averages and has beaten earnings estimates for the last three quarters. Recent news includes major contracts for subsea systems and LNG technology, supporting revenue growth. Analyst consensus is strongly positive with a $73.25 price target, indicating ~13% upside from current levels.
Outlook remains favorable driven by energy infrastructure demand and operational execution, though risks include oil price volatility and integration challenges from the Chart acquisition. The stock offers growth potential with solid cash flow and margin expansion, but investors should monitor debt levels and global energy spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →
